LaSalle St. Investment Advisors LLC Buys 1,960 Shares of Johnson & Johnson (NYSE:JNJ)

LaSalle St. Investment Advisors LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 22.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 10,580 shares of the company’s stock after purchasing an additional 1,960 shares during the quarter. LaSalle St. Investment Advisors LLC’s holdings in Johnson & Johnson were worth $1,530,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. IFS Advisors LLC lifted its position in shares of Johnson & Johnson by 138.9% in the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after acquiring an additional 100 shares during the period. WealthTrak Capital Management LLC acquired a new stake in Johnson & Johnson during the fourth quarter worth $26,000. Mountain Hill Investment Partners Corp. bought a new stake in Johnson & Johnson in the 4th quarter valued at $29,000. Bay Harbor Wealth Management LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at $32,000. Finally, Conquis Financial LLC bought a new position in shares of Johnson & Johnson during the 4th quarter worth about $33,000. Institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on JNJ. Raymond James dropped their price target on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Bank of America dropped their target price on Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating for the company in a report on Thursday. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Barclays increased their price objective on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Tuesday, January 28th. Finally, Wells Fargo & Company reduced their target price on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Eight investment analysts have rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $171.67.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $151.62 on Monday. The stock has a market cap of $365.39 billion, a price-to-earnings ratio of 22.80, a P/E/G ratio of 2.56 and a beta of 0.49. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The business’s 50-day simple moving average is $159.40 and its 200 day simple moving average is $155.17.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. During the same period in the previous year, the firm posted $2.29 earnings per share. Johnson & Johnson’s revenue for the quarter was up 5.3% compared to the same quarter last year. As a group, research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Insider Activity at Johnson & Johnson

In other news, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares of the company’s stock, valued at $2,357,552.70. The trade was a 2.60 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the firm’s stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares in the company, valued at $3,483,645.88. The trade was a 25.00 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.